mind medicine mindmed glp-1 receptor agonist medications New Guidelines for Type 2 Diabetes in 2025 GLP-1 receptor agonists improve mood

[162] In March 2023, a Novo Nordisk official said, based on a randomized, double-blind study (NCT03548935 [163] ) funded by the company, that people using semaglutide to lose weight regained two-thirds of their original weight loss one year (52 weeks) after discontinuing use of the drug

In comparison with the overweight/obese reference group, which had a rate of major birth defects of 3.9%, the adjusted OR was 0.54 (95% CI, 0.11 to 2.75)

As a dual agonist, it targets both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

[DOI] [PMC free article] [PubMed] [Google Scholar] 115.Filippatos TD, Panagiotopoulou TV, Elisaf MS

Literature / References M.E